Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Yizhao Xie"'
Autor:
Shihui Hu, Yannan Zhao, Yizhao Xie, Shuhui You, Xichun Hu, Jian Zhang, Leiping Wang, Jun Cao, Chengcheng Gong, Biyun Wang
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
ObjectiveWith the approval of trastuzumab deruxtecan for the treatment of unresectable/metastatic HER2-low breast cancer, human epidermal growth factor receptor 2 (HER2)-low has emerged as a clinically actionable biomarker. There is an urgent need fo
Externí odkaz:
https://doaj.org/article/3d5bed5376144891810c7abd19b8248f
Autor:
Guang Ma, Shuhui You, Yizhao Xie, Bingxin Gu, Cheng Liu, Xichun Hu, Shaoli Song, Biyun wang, Zhongyi Yang
Publikováno v:
Cancer Imaging, Vol 23, Iss 1, Pp 1-8 (2023)
Abstract Objective Intra-tumoral heterogeneity of 18F‐fluorodeoxyglucose (18F‐FDG) uptake has been proven to be a surrogate marker for predicting treatment outcome in various tumors. However, the value of intra-tumoral heterogeneity in metastatic
Externí odkaz:
https://doaj.org/article/e5a09c0e73834eac9ad0bdbae032ea73
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Pyrotinib, an irreversible pan-human epidermal growth (HER) inhibitor, has proven its antitumor efficacy as a second-line treatment for HER2-positive metastatic breast cancer (HER2+ MBC) when combined with capecitabine. However, real-worl
Externí odkaz:
https://doaj.org/article/4dea617c19ac4795a7ea69e24afcf9ae
Autor:
Shuhui You, Yizhao Xie, Mengjing Ji, Cheng Liu, Yannan Zhao, Chengcheng Gong, Shihui Hu, Yumeng Li, Zhongyi Yang, Biyun Wang
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: The 18F-fluoroestradiol positron emission tomography/computed tomography (18F-FES PET/CT) technique provides a convenient method to evaluate the overall estrogen receptor (ER) expression in metastatic breast cancer (MBC) patients. There a
Externí odkaz:
https://doaj.org/article/780dbc0555ed448086747b2f4b2c8e82
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2023)
ObjectivePyrotinib and pertuzumab are effective treatment options for HER2-positive metastatic breast cancer (HER2+ MBC). Our study was to directly compare the efficacy and safety of pyrotinib plus trastuzumab (PyroH) and pertuzumab plus trastuzumab
Externí odkaz:
https://doaj.org/article/8498e7ce732f4014bdb8a05c40ff20e6
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2023)
ObjectiveDespite the promising efficacy of the novel antibody-drug conjugate trastuzumab deruxtecan in treating Hormone Receptor (HoR)-positive/Human Epidermal Growth Factor Receptor 2 (HER2)-low metastatic breast cancer (MBC), its categorization as
Externí odkaz:
https://doaj.org/article/ee6bef37d6d94cbbaf517c1f0c616794
Autor:
Jinyan Wang, Zhonghua Tao, Biyun Wang, Yizhao Xie, Ye Wang, Bin Li, Jianing Cao, Xiaosu Qiao, Dongmei Qin, Shanliang Zhong, Xichun Hu
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionCuproptosis is a novel copper-dependent regulatory cell death (RCD), which is closely related to the occurrence and development of multiple cancers. However, the potential role of cuproptosis-related genes (CRGs) in the tumor microenviron
Externí odkaz:
https://doaj.org/article/2f2048a5fb744a92a075b6d11cc138f4
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-5 (2022)
Abstract Ferroptosis, a novel non-apoptotic form of cell death, can induce tumor cell death and treatment resistance. Lipid metabolism is closely related to ferroptosis; however, the effect of mammary adipocytes on breast cancer ferroptosis remains t
Externí odkaz:
https://doaj.org/article/0d39dc085ee04ecfbb3306d0f32b1da5
Autor:
Yizhao Xie, Cheng Liu, Yannan Zhao, Chengcheng Gong, Yi Li, Shihui Hu, Shaoli Song, Xichun Hu, Zhongyi Yang, Biyun Wang
Publikováno v:
Cancer Medicine, Vol 11, Iss 9, Pp 1948-1955 (2022)
Abstract Background Recently, immunotherapy has been used to treat metastatic triple‐negative breast cancer (mTNBC). Basic research has indicated a relation between tumor heterogeneity and the immune response. Tumor heterogeneity derived from 18F
Externí odkaz:
https://doaj.org/article/340505441ac64333b2f87a683c90ebaf
Autor:
Chengcheng Gong, Yizhao Xie, Yannan Zhao, Yi Li, Jian Zhang, Leiping Wang, Jun Cao, Zhonghua Tao, Xichun Hu, Biyun Wang
Publikováno v:
Therapeutic Advances in Drug Safety, Vol 13 (2022)
Purpose: Weekly gemcitabine + paclitaxel (wGT) administration is widely applied in real-world clinical practice. The 28-day and 21-day regimens of wGT are the most widely accepted regimens. We evaluated the efficacy and safety of wGT administration i
Externí odkaz:
https://doaj.org/article/9d8349ec24df4118a29d8a50147b661e